Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Assets (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Non-Current Assets data on record, last reported at $353.5 million in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 64.62% year-over-year to $353.5 million; the TTM value through Sep 2025 reached $353.5 million, down 86.88%, while the annual FY2024 figure was $344.6 million, 9.18% up from the prior year.
  • Non-Current Assets reached $353.5 million in Q3 2025 per AMPH's latest filing, down from $1.0 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.0 billion in Q2 2025 and bottomed at $264.6 million in Q4 2022.
  • Average Non-Current Assets over 5 years is $516.8 million, with a median of $348.0 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: skyrocketed 238.78% in 2023, then crashed 64.62% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $271.5 million in 2021, then dropped by 2.55% to $264.6 million in 2022, then increased by 19.3% to $315.6 million in 2023, then rose by 9.18% to $344.6 million in 2024, then increased by 2.58% to $353.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $353.5 million in Q3 2025, $1.0 billion in Q2 2025, and $353.8 million in Q1 2025.